Bradley Canino
Stock Analyst at Stifel
(1.57)
# 3,379
Out of 5,182 analysts
83
Total ratings
33.78%
Success rate
-3.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintains: Buy | $9 → $8 | $1.76 | +354.55% | 2 | Mar 24, 2026 | |
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $15.23 | +149.51% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $21.00 | +109.52% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.92 | +413.70% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $1.59 | -5.66% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $13.25 | +43.40% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $14.95 | +53.85% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $10.29 | +395.63% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $9.07 | +109.48% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $125.68 | -66.58% | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $40 | $22.12 | +80.83% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $104.04 | +29.76% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $10.19 | +96.27% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $4.25 | +135.29% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $2.83 | +394.70% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $86.68 | -36.55% | 4 | Feb 23, 2024 |
Pyxis Oncology
Mar 24, 2026
Maintains: Buy
Price Target: $9 → $8
Current: $1.76
Upside: +354.55%
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $15.23
Upside: +149.51%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $21.00
Upside: +109.52%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.92
Upside: +413.70%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $1.59
Upside: -5.66%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $13.25
Upside: +43.40%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $14.95
Upside: +53.85%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $10.29
Upside: +395.63%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $9.07
Upside: +109.48%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $125.68
Upside: -66.58%
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $22.12
Upside: +80.83%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $104.04
Upside: +29.76%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $10.19
Upside: +96.27%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $4.25
Upside: +135.29%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $2.83
Upside: +394.70%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $86.68
Upside: -36.55%